Radiation plus abemaciclib for breast cancer that spread to the brain
Official title: SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests radiation and the drug abemaciclib for a type of breast cancer that has spread to the brain.
Read our full plain-language summary
What the trial team says
This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
Key facts
- Registry number
- NCT04923542
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Brain Metastases, HR+ Metastatic Breast Cancer
Where it is running
This trial lists 2 sites.
-
Florida
- Moffitt Cancer Center (Tampa)
-
Ohio
- Ohio State University Comprehensive Cancer Center (Columbus)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.